PI
AEGR

Putnam Investments’s Aegerion Pharmaceuticals AEGR Stock Holding History

Putnam Investments’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,101,444
Closed -$4.08M – 1463
2016
Q1 		$4.08M Sell
1,101,444
-323,856
-23% -$2.01M 0.01% 718
2015
Q4 		$14.4M Sell
1,425,300
-488,300
-26% -$5.88M 0.03% 371
2015
Q3 		$26M Sell
1,913,600
-91,174
-5% -$1.62M 0.06% 266
2015
Q2 		$38M Sell
2,004,774
-325,200
-14% -$7.04M 0.08% 236
2015
Q1 		$61M Sell
2,329,974
-598,200
-20% -$15.2M 0.12% 182
2014
Q4 		$61.3M Sell
2,928,174
-645,572
-18% -$16.3M 0.13% 172
2014
Q3 		$119M Buy
3,573,746
+121,650
+4% +$3.78M 0.25% 94
2014
Q2 		$111M Buy
3,452,096
+1,546,484
+81% +$57.6M 0.24% 100
2014
Q1 		$87.9M Buy
1,905,612
+1,893,486
+15,615% +$111M 0.2% 119
2013
Q4 		$860K Sell
12,126
-192
-2% -$14.7K ﹤0.01% 1239
2013
Q3 		$1.06M Sell
12,318
-1,101
-8% -$93.3K ﹤0.01% 1206
2013
Q2 		$850K Buy
+13,419
New +$712K ﹤0.01% 1229

Other funds holding AEGR

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Putnam Investments's AEGR Position: Q2 2016 in Review

Putnam Investments sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 1,101,444 shares — an estimated $4.08M sold.

Putnam Investments first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $119M in Q3 2014. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Putnam Investments reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Putnam Investments sold 1,101,444 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $4.08M.
  • Putnam Investments first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Putnam Investments's Aegerion Pharmaceuticals position peaked at $119M in Q3 2014.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Putnam Investments's 13F filing for Q2 2016, filed 15 Aug 2016.